South Korea · Delayed Price · Currency is KRW Access Bio Statistics
Total Valuation
Access Bio has a market cap or net worth of KRW 90.40 billion. The enterprise value is -140.81 billion.
| Market Cap | 90.40B |
| Enterprise Value | -140.81B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Access Bio has 35.17 million shares outstanding. The number of shares has increased by 29.51% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 35.17M |
| Shares Change (YoY) | +29.51% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 0.30% |
| Float | 25.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.84 |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of 0.13.
| Current Ratio | 6.95 |
| Quick Ratio | 6.41 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.18 |
| Interest Coverage | -42.31 |
Financial Efficiency
Return on equity (ROE) is -19.37% and return on invested capital (ROIC) is -26.37%.
| Return on Equity (ROE) | -19.37% |
| Return on Assets (ROA) | -6.86% |
| Return on Invested Capital (ROIC) | -26.37% |
| Return on Capital Employed (ROCE) | -12.28% |
| Weighted Average Cost of Capital (WACC) | 4.19% |
| Revenue Per Employee | 233.05M |
| Profits Per Employee | -1.10B |
| Employee Count | 101 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 3.15 |
Taxes
| Income Tax | -30.58B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.14% in the last 52 weeks. The beta is 0.34, so Access Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -51.14% |
| 50-Day Moving Average | 2,299.20 |
| 200-Day Moving Average | 3,113.20 |
| Relative Strength Index (RSI) | 63.44 |
| Average Volume (20 Days) | 156,520 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Access Bio had revenue of KRW 23.54 billion and -110.91 billion in losses. Loss per share was -3,149.61.
| Revenue | 23.54B |
| Gross Profit | -31.90B |
| Operating Income | -71.24B |
| Pretax Income | -141.94B |
| Net Income | -110.91B |
| EBITDA | -57.63B |
| EBIT | -71.24B |
| Loss Per Share | -3,149.61 |
Balance Sheet
The company has 321.46 billion in cash and 73.23 billion in debt, with a net cash position of 248.22 billion or 7,056.99 per share.
| Cash & Cash Equivalents | 321.46B |
| Total Debt | 73.23B |
| Net Cash | 248.22B |
| Net Cash Per Share | 7,056.99 |
| Equity (Book Value) | 549.93B |
| Book Value Per Share | 15,156.81 |
| Working Capital | 304.74B |
Cash Flow
In the last 12 months, operating cash flow was -60.66 billion and capital expenditures -1.40 billion, giving a free cash flow of -62.05 billion.
| Operating Cash Flow | -60.66B |
| Capital Expenditures | -1.40B |
| Depreciation & Amortization | 13.61B |
| Net Borrowing | -36.15B |
| Free Cash Flow | -62.05B |
| FCF Per Share | -1,764.15 |
Margins
| Gross Margin | -135.52% |
| Operating Margin | -302.64% |
| Pretax Margin | -603.04% |
| Profit Margin | n/a |
| EBITDA Margin | -244.82% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Access Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.51% |
| Shareholder Yield | -29.51% |
| Earnings Yield | -122.69% |
| FCF Yield | -68.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Access Bio has an Altman Z-Score of 2.32 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.32 |
| Piotroski F-Score | 1 |